Abstract
Faecal microbiota transplantation is effective in treating recurrent Clostridium difficile infections whether delivered by oral capsule or colonoscopy, according to new research. Dina Kao and colleagues randomly assigned patients to receive a faecal microbiota transplant via oral capsule (n=57) or via colonoscopy (n=59). The absence of recurrent C difficile infections was achieved in 96·2% of patients, both in the capsule group (51/53) and the colonoscopy group (50/52) after a single treatment (difference: 0%, one-sided 95% CI −6·1 to infinity; p<0·001). Minor adverse events were more common in the colonoscopy group than in the oral group (12·5% vs 5·4%). Significantly more participants receiving capsules rated their experience as “not at all unpleasant” (66% vs 44%; p=0·01). These findings suggest that delivery via oral capsule could broaden and improve the use of faecal microbiota transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
